Results 171 to 180 of about 25,222 (249)

Buprenorphine-Naloxone vs Extended-Release Naltrexone Following Opioid Withdrawal Treatment.

JAMA Netw Open
Hsu HE, Lodi S, Yan S, Bovell-Ammon BJ, Christine PJ, Tilhou AS, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz JM, Walley AY, Larochelle MR.   +12 more
europepmc   +1 more source

Logistic and patient preference-driven therapeutic stance in an opioid-dependent pregnant female: A case report. [PDF]

Indian J Psychiatry
Sanahan R, Pourush S, Tomar S, Mandal P, Sarkar S.   +4 more
europepmc   +1 more source

Reconsidering the usefulness of using long-acting injectable buprenorphine as a tapering tool: a case report of delayed withdrawal months after last dose. [PDF]

Front Psychiatry
Woods K, Graham S, Dobscha S, Blazes C.
europepmc   +1 more source

Hold on tight: the kinetic profiling of opioid receptor ligands using the CORAL-MD. [PDF]

J Cheminform
Kurowska K, Rorat W, Kordylewski SK, Podlewska S.   +3 more
europepmc   +1 more source

Projected budget impact of pharmacotherapy scenarios for obesity and related conditions in Peru: A national survey analysis of 76,819 participants. [PDF]

Obes Pillars
Vera Ponce VJ.
europepmc   +1 more source

Pharmacological Management of Opioid Use Disorder: A Systematic Review and Network Meta-Analysis: Prise en charge pharmacologique du trouble de l'usage des opiacés : revue systématique et méta-analyse en réseau. [PDF]

Can J Psychiatry
Rodrigues M, Dennis BB, Sadeghirad B, Oprea A, Malik M, Naji LN, McEvoy A, Malhotra D, Parpia S, Thabane L, Samaan Z.   +10 more
europepmc   +1 more source

Opioid Use Disorder Treatment Gaps and Emerging Therapeutics to Address Them. [PDF]

CNS Drugs
Banks ML.
europepmc   +1 more source

Effectiveness of Naltrexone and Baclofen Combination in Reducing Craving among Patients with Alcohol Dependence: An Open-label Trial. [PDF]

Clin Psychopharmacol Neurosci
Naqvi A, Nischal A, Singh A, Nischal A.
europepmc   +1 more source

Co-treating opioid and alcohol use disorders in the United States, 1960-2026: A historical policy review in the glucagon-like peptide-1 (GLP-1) era. [PDF]

Drug Alcohol Depend Rep
Qeadan F, Barbeau WA.
europepmc   +1 more source